BioCryst Pharmaceuticals, Inc. BCRX · NASDAQ
$7.79 -2.87% (-$0.23)
Summary
54 / 100 · Bulios Score
What speaks for it
- Revenue grew by 48% a year over the last 3 years.
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 38 USD is left as free cash.
What to watch
- The company made a loss over the last 12 months.
- Analysts expect revenue to fall by 19% this fiscal year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 118% a year over 5 years. Over the last 3 years it grew by 48% a year. For the next fiscal year analysts expect revenue to fall by 19%.
Growth in detailDoes it make money?
ReasonablyOver the last 12 months it made a loss of $384.7M.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 1.1 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 23
- Hold 6
- Sell 0
Today's price within the analysts' price targets
The average target of $19 is 144% above today's price. 79% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 71%
- License 28%
- Collaborative And Other Research And Development 0.9%
By region
The company reports no revenue by region.
Product brings in 71% of revenue. Collaborative And Other Research And Development grew fastest, by 230% a year.
Segments in detail